Bailard, Inc. Arvinas, Inc. Transaction History

Bailard, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $241,560 - $355,971	-3,300 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$58.19 - $91.37 $477,158 - $749,234	-8,200 Reduced 71.3%	3,300 $218,000
Q4 2020 Feb 03, 2021	BUY	$20.19 - $84.93 $54,513 - $229,311	2,700 Added 30.68%	11,500 $977,000
Q2 2020 Aug 12, 2020	SELL	$29.88 - $56.74 $8,964 - $17,022	-300 Reduced 3.3%	8,800 $295,000
Q1 2020 Apr 16, 2020	SELL	$33.0 - $54.5 $161,700 - $267,050	-4,900 Reduced 35.0%	9,100 $367,000
Q4 2019 Jan 31, 2020	BUY	$15.39 - $44.38 $215,460 - $621,320	14,000 New	14,000 $575,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.